ANO1 and head and neck squamous cell carcinoma: It was found that the amplification and high expression of TMEM16A in HNSCC cells were more sensitive to gefitinib, suggesting that overexpression of TMEM16A could be used as a predictor of EGFR targeting response in HNSCC therapy.